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(E)-28-deoxy-28-(fluoromethylene) cytidine (FMdC), a novel
inhibitor of ribonucleotide-diphosphate reductase, has been
shown to have anti-tumor activity against solid tumors and
sensitize tumor cells to ionizing radiation. Pentoxifylline
(PTX) can potentiate the cell killing induced by DNA-
damaging agents through abrogation of DNA-damage-
dependent G2 checkpoint. We investigated the cytotoxic,
radiosensitizing and cell-cycle effects of FMdC and PTX in a
human colon-cancer cell line WiDr. PTX at 0.25–1.0 mM
enhanced the cytotoxicity of FMdC and lowered the IC50 of
FMdC from 79 6 0.1 to 31.2 6 2.1 nM, as determined by MTT
assay. Using clonogenic assay, pre-irradiation exposure of
exponentially growing WiDr cells to 30 nM FMdC for 48 hr or
post-irradiation to 0.5 to 1.0 mM PTX alone resulted in an
increase in radiation-induced cytotoxicity. Moreover, there
was a significant change of the radiosensitization if both drugs
were combined as compared with the effect of either drug
alone. Cell-cycle analysis showed that treatment with nano-
molar FMdC resulted in S-phase accumulation and that such
an S-phase arrest can be abrogated by PTX. Treatment with
FMdC prior to radiation increased post-irradiation-induced
G2 arrest, and such G2 accumulation was also abrogated by
PTX. These results suggest that pharmacological abrogation
of S and G2 checkpoints by PTX may provide an effective
strategy for enhancing the cytotoxic and radiosensitizing
effects of FMdC. Int. J. Cancer 80:155–160, 1999.
r 1999 Wiley-Liss, Inc.
(E)-28-deoxy-28-(fluoromethylene) cytidine(FMdC) has been syn-
thesized as a mechanism-based inhibitor of ribonucleotide-
diphosphate reductase (Bitonti et al., 1995), and is presently in
Phase-I clinical trial. Ribonucleotide reductase is a key enzyme in
DNA synthesis. This enzyme has increased activity in rapidly
growing tumors, and represents a potential target for chemotherapy.
In contrast to other inhibitors of RR, such as hydroxyurea and
ara-C, which are widely used in the treatment of leukemias and
show limited or no anti-tumor activity against solid tumor, FMdC is
a promising novel chemotherapeutic agent with striking activity in
a variety of solid-tumor cells (Bitonti et al., 1995; Piepmeier et al.,
1996). Several experimental studies have demonstrated that FMdC
sensitized human colon- and cervical-cancer cells and mouse
mammary-tumor cells to radiation in vitro (Snyder, 1994; Li et al.,
1996), and we have reported that the anti-tumor and radiosensitiz-
ing effects are also evident in vivo (Sun et al., 1997).
Methylxanthines such as caffeine enhance cytotoxicity induced
by DNA-damaging agents (Lau and Pardee, 1982). Caffeine and
pentoxifylline (PTX) potentiate the cytotoxicity of several chemo-
therapeutic drugs such as cisplatin, camptothecin and alkylating
compounds (Fan et al., 1995; Teicher et al., 1991). In contrast,
those compounds antagonize the cytotoxic effect of doxorubicin.
Preferential sensitization has been reported using a combination of
caffeine and ionizing radiation or caffeine and cisplatin (Russell et
al., 1995). In all these studies, the sensitization is explained by the
preferential abrogation of the G2 checkpoint in cells lacking p53
function. FMdC acts as a novel anti-tumor drug and the modulation
of its cytotoxicity and radiosensitization by PTX has never been
evaluated.
In the present study, we used a human colon-cancer cell line
(WiDr), known to be p53-mutated, to investigate whether PTX
enhances FMdC-mediated cytotoxicity and radiation sensitization.
In addition, we tried to assess whether PTX can affect cell-cycle
distribution induced by FMdC and irradiation. From our findings,
we may conclude that PTX abrogates FMdC-induced S-phase
arrest and radiation-induced G2 arrest. These effects on cell-cycle
blocks may explain, at least in part, the enhancement of both the
cytotoxicity and the radiosensitizing potential of FMdC on WiDr
cells in vitro.
MATERIALS AND METHODS
Chemicals and cell culture
FMdC (MDL 101,731), kindly provided by Hoechst Marion
Roussel (Cincinnati, OH), was dissolved in distilled water. Di-
methyl sulfoxide (DMSO) and 3-(4,5,-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from Sigma
(Buchs, Switzerland). MTT was dissolved at a concentration of 5
mg/ml in RPMI-1640 medium without phenol red, filtered, then
frozen at 280°C for storage. PTX was a gift from Hoechst
(Frankfurt, Germany). PTX was dissolved in PBS to 100 mM stock
solution and stored at 220°C.
The human colon-cancer cell line WiDr was obtained from the
ATCC (Rockville, USA). Cells were maintained in minimum
essential medium containing 10% fetal bovine serum (FBS), 1%
non-essential aminoacids and 2 mM L-glutamine. The cells were
incubated in a humidified 5% CO2 atmosphere at 37°C. In these
conditions, the mean doubling time of the exponentially growing
cells was 23 hr.
MTT assay
The cytotoxic interaction of FMdC and PTX was analyzed using
a MTT assay as described (Li et al., 1997). Briefly, the WiDr cells
(4000 cells/well) were seeded in duplicate in 96-well plates; at the
same time, drug-containing medium was added. FMdC was used in
concentrations ranging from 10 nM to 320 nM, and PTX was used
at a concentration from 0.25 mM to 4.0 mM. FMdC and PTX were
added simultaneously. After 3-day incubation, 100 µl MTT were
added to each well and incubated for 4 hr at 37°C. The supernatants
were removed and formazan crystals were re-suspended in 200 µl
of DMSO. The plates were shaken for 5 min, then the optical
densities (OD) of each well were read at 570 nm, with the reference
wavelength set at 690 nm using a SLT SPECTRA II (Tecan,
Hombrechtikon, Switzerland) plate recorder. Cell survival was
calculated as the percentage absorbance of untreated cells (Li et al.,
1997). The IC50 (50% inhibitory concentration) values were
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defined as the drug concentrations inducing a 50% reduction in the
OD as compared with untreated cells.
Clonogenic assay
Assessment of the radiosensitization observed with FMdC alone,
with PTX alone and with the combination of both drugs was made
by clonogenic assay. The WiDr cells, in conditions of exponential
growth, were treated with FMdC prior to irradiation, trypsinized,
and re-suspended in fresh medium. In preliminary experiments, we
observed, as expected for a nucleoside analogue, the marked effect
of prolonged exposure prior to irradiation on the radiosensitizing
capacity of FMdC. After trypsinization, an appropriate number of
cells was plated into 60-mm2 tissue-culture dishes. After 3-hr
incubation, introduced to obtain maximal cell attachment, the
dishes were irradiated at a dose rate of 80.2 cGy/min with an Oris
IBL cesium-37 source at room temperature. PTX was added
immediately following irradiation, since we expected PTX to be
active on the post-irradiation G2/M block. After 2 weeks, colonies
were visualized by staining with crystal violet, and colonies of 50
cells or more were counted. All colony counts were adjusted for
plating efficiency (PE) to yield corrected survival of 100% for
untreated controls. Similarly, colony counts for PTX-treated cells
were adjusted for drug toxicity to yield corrected survival of 100%
for unirradiated PTX-treated controls. Radiosensitization is ex-
pressed as an enhancement ratio, defined as the mean survival
fraction (SF) for control/mean SF for FMdC and/or PTX.
Flow cytometry
Cells were processed in the same way as for cell survival. WiDr
cells in the exponential-growth phase were treated by FMdC alone,
by irradiation alone, or by FMdC 1 irradiation in the presence or
the absence of PTX. The cells were harvested at the indicated time,
fixed in 70% alcohol, and stored in the dark at 4°C for at least 24 hr
until analysis.
After fixation, cells were washed twice in ice-cold PBS contain-
ing 200 U/ml RNase A. Cellular DNA was stained with 3 ml 0.5
mg/ml propidium-iodide solution. Cell-cycle determination was
performed on a FACScan flow cytometer (Becton Dickinson,
Mountain View, CA), using the cellfit software. Results are
expressed as a percentage of total cells at a specific cell phase.
Statistical analysis
Each experiment was repeated 2 or 3 times. Data are presented as
the mean 6 the standard error of 2 or independent experiments.
Means were compared by the Student’s 2-tailed t-test. A difference
was considered significant if a value of 0.05 was reached. ANOVA
was used to test the main effects of FMdC and PTX alone, and their
interaction of radiosensitization. Isobologram analysis was used to
evaluate the cytotoxic interaction of FMdC and PTX (Chou and
Talalay, 1984).
RESULTS
Potentiation of FMdC cytotoxicity by PTX
The cytotoxic effect of FMdC and PTX on WiDr was measured
with an MTT assay after 3-day exposure. The IC50 was 79.0 6 1.0
nM for FMdC and 2.7 6 0.1 mM for PTX. PTX alone, up to
concentrations of 1 mM, had a minimal effect on the viability of
WiDr-cells, with approximately 80% cell survival. A 3-day expo-
sure to 0.25–1.0 mM PTX resulted in a significant increase of
FMdC cytotoxicity in a dose-dependent manner (Fig. 1a). Addition
of 0.25, 0.5 and 1.0 mM PTX to various concentrations of FMdC
lowered the IC50 of FMdC to 54.3 6 2.2 nM, 37.0 6 1.2 nM, and
31.2 6 2.1 nM respectively. Isobologram analysis showed that the
cytotoxicity of FMdC and PTX was supra-additive (Fig. 1b).
Enhancement of FMdC radiosensitization by PTX
We investigated first the importance of the duration of exposure
to FMdC on cytotoxicity and on radiosensitization. As found for
FIGURE 1 – Effect of PTX on FMdC cytotoxicity using a 3-day MTT assay. (a) Survival rate of FMdC in the presence of 0.25 to 1.0 mM PTX.
Cells were treated with different concentrations of FMdC with or without PTX. (b) Isobologram analysis showing a supra-additive cytotoxic effect
of FMdC and PTX.
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plating efficiency (PE), the decrease in the surviving fraction after
irradiation, compared with corresponding controls (Fig. 2a), did
not occur if cells were exposed for 6 to 24 hr to 30 nM FMdC (Fig.
2b). In contrast, after 48 hr exposure to 30 nM FMdC there was a
significant decrease in the surviving fraction, compared with
irradiated controls, preceding in time the significant reduction in
PE observed in unirradiated but FMdC-treated cells (Fig. 2a,b).
To assess the effect of PTX on FMdC radiosensitization, cells
were incubated for 48 hr prior to radiation with 30 nM FMdC and
PTX was added immediately after irradiation. As noted above, no
significant cytotoxicity but measurable radiosensitization was
observed with FMdC at this time point by clonogenic assay. PTX
alone at concentrations of 0.25 to 1.0 mM had minimal cytotoxic-
ity, with a PE of 92%. In Figure 3a, the radiosensitizing effect of 30
nM FMdC in the presence or the absence of 0.5 mM PTX on WiDr
cells has been plotted. PTX alone at concentrations of 0.5 mM and
1.0 mM enhanced the cell killing induced by irradiation. The
enhancement ratios (ER) at the clinical relevant fraction dose of 2
Gy were 1.22 6 0.03 for 30 nM FMdC alone, 1.23 6 0.03 for 0.5
mM PTX and 1.4 6 0.15 for 1.0 mM PTX alone. In contrast, 0.25
mM PTX alone had no significant effect on radiosensitization (data
not shown). However, addition of 0.5 to 1.0 mM PTX resulted in an
increase of FMdC-mediated radiosensitization. When cells were
treated with 30 nM FMdC in the presence of 0.5 and 1.0 mM PTX,
the corresponding ER ranged from 1.69 6 0.03 to 2.04 6 0.32. In
Figure 3b, we reported the radiosensitization of WiDr cells as a
function of FMdC concentration in the presence of 0.5 mM PTX.
WiDr cells were exposed to varying concentrations of FMdC
(10–50 nM) for 48 hr prior to a single dose of 2 Gy irradiation. The
survival of irradiated cells decreased gradually as the drug concen-
tration increased from 20 to 50 nM. Whatever the concentration of
FMdC used, 0.5 mM PTX yielded an additive effect on FMdC
radiosensitization.
Effect of FMdC alone on cell-cycle distribution
To investigate the effect of FMdC on cell-cycle progression,
asynchronous exponentially growing cells were treated with FMdC
for 6 to 48 hr, then subjected to DNA analysis by flow cytometry.
Exposure of WiDr cells to 20 to 40 nM FMdC alone resulted in an
arrest of cells in S phase in a concentration-dependent manner, as
compared with the control (Fig. 4). In contrast, FMdC at the lower
concentration of 10 nM had no detectable effect on cell-cycle
distribution. At 20 nM FMdC, significant S-phase accumulation is
observed only at 48 hr after treatment. S-phase arrest induced by 30
nM and 40 nM FMdC appeared at 12 hr, peaks at 24 hr, and reached
a plateau at 48 hr after treatment. Such S-phase arrest was
paralleled by depletion of G1 and G2M phase (data not shown).
PTX abrogation of FMdC-induced S-phase arrest
To examine the potential of PTX to influence FMdC-induced
cell-cycle perturbation, cells were treated for 24 hr with 30 nM
FMdC in the presence of PTX. At concentrations up to 1 mM, PTX
alone had no detectable effect on cell-cycle progression of un-
treated control cells (data not shown). At 24 hr after treatment with
30 nM FMdC, addition of 0.25 to 1.0 mM PTX abrogated
FMdC-induced S-phase arrest in a dose-dependent manner (Fig. 5).
PTX at concentrations of 0.5 mM and 1.0 mM reduced S-phase
arrest from 66.5 6 0.9% to 54.4 6 1.2% and to 39.3 6 1.4%
respectively. The reduction of S-phase arrest by PTX was paral-
leled by an increase in G1 and G2M phase (Fig. 5b).
Effect of PTX on G2 arrest induced by radiation
with or without FMdC
We have demonstrated that irradiation resulted in dose-
dependent G2 arrest in WiDr cells and that this G2 arrest can be
over-ridden by PTX (Li et al., 1998). In the present study, we
investigated further whether pre-irradiation exposure of WiDr cells
to FMdC affects irradiation-induced G2 arrest, and whether PTX
abrogates this G2 arrest after FMdC treatment. Cells were treated
with 30 nM FMdC for 48 hr prior to radiation, then irradiated
incubated with 0.5 mM PTX for 24 hr. Flow-cytometry analysis
confirms our observation that PTX inhibits the G2 arrest induced by
radiation (Fig. 6). Moreover, the pre-irradiation treatment with 30
nM FMdC for 48 hr results in an increase in G2 arrest in irradiated
cells. Such G2/M accumulation observed after FMdC treatment and
irradiation is significantly abrogated by 0.5 mM PTX (Fig. 6).
DISCUSSION
The data reported in this study demonstrate that PTX as a biological
response modifier is able to modify the intrinsic toxicity of FMdC and
sensitize WiDr cells in vitro to ionizing irradiation. The human
colon-cancer WiDr cells exposed to nanomolar concentrations of FMdC
are characterized by S-phase arrest. This latter can be abrogated by
exposure to PTX, and this correlates with enhancement of the cytotoxic
effect of FMdC, while the radiosensitizing effect of FMdC is also
enhanced by PTX. This observation is compatible with the observed
abrogation of G2 arrest by PTX, determined by flow cytometry on cells
exposed to irradiation and FMdC. Our experiments therefore suggest
that PTX is a potent inhibitor of cell-cycle arrest, both in S and in G2, and
that this abrogation of cell-cycle blocks increases the cytotoxic and
radiosensitizing effects of FMdC.
The mechanism by which FMdC produces cytotoxicity and
radiosensitization is much less clear. While FMdC shares some
metabolic similarities with other ribonucleotide-reductase inhibi-
tors, such as ara-C, hydroxyurea and gemcitabine, these drugs have
markedly different anti-tumor effects (Bitonti et al., 1995; Shewach
et al., 1994; Iwasaki et al., 1997). Presumably, FMdC is a
mechanism-based, irreversible inhibitor of ribonucleotide reduc-
tase. It is possible that this drug acts in a manner similar to other
ribonucleotide-reductase inhibitors, such as 28,28-difluorocytidine
(gemcitabine). The latter has been shown to cause inhibition of
DNA synthesis without significantly inhibiting either protein or
RNA synthesis (Huang et al., 1991). Inhibition of DNA synthesis with
FIGURE 2 – Cytotoxicity and radiosensitization of FMdC as a
function of time. Cells were exposed to 30 nM FMdC for the indicated
time periods, and clonogenicity was assessed with or without 6 Gy. (a)
Effect of FMdC alone on cell survival or plating efficiency (PE). (b)
Survival of cells treated with 6 Gy with or without 30 nM FMdC at the
indicated time point.
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gemcitabine might be due to decreased deoxynucleotide pools (Fox,
1993), or to chain termination after being converted to the triphosphate
(Huang et al., 1991). Shewach et al. (1994) reported that the depletion of
deoxyribonucleoside 58-triphosphate (dNTP) pools by gemcitabine may
also contribute to its radiosensitizing effect.
The S-phase arrest induced by nanomolar FMdC in the present
study is in accordance with other data: whatever the exact
mechanism of DNA-synthesis inhibition, the ultimate effect is an
S-phase block (Plunkett et al., 1989; Paulovich and Hartwell,
1995). S-phase arrest can also be induced by other DNA-damaging
agents, such as camptothecin, cisplatin and bleomycin (Perras et
al., 1993; Shao et al., 1997; Paulovich and Hartwell, 1995;
Goldwasser et al., 1996). Block in the DNA-synthetis phase of the
cell cycle by FMdC is expected, since the ribonucleotide-reductase
FIGURE 3 – Potentiation of FMdC radiosensitization by PTX. Cells were treated with FMdC for 48 hr and irradiated, after which PTX was
added immediately. (a) Survival fraction of cells exposed to 30 nM FMdC in the presence of 0.5 to 1.0 mM PTX. (b) Surviving fraction of cells as
a function of dose of FMdC (0–50 nM) with or without 0.5 mM PTX. Cells were exposed to FMdC for 48 hr before irradiation at 2 Gy.
FIGURE 4 – Effect of FMdC alone on cell-cycle distribution as a function of concentration. Cells were treated with varying concentrations of
FMdC for the different time periods. *Values significantly different from control ( p , 0.05).
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activity is cell-cycle dependent, being induced essentially when
cells are passing from G1 to S (Eriksson et al., 1984). However,
more basic research will be required before we can reach a
conclusion on the metabolism and mechanisms of cytotoxicity and
radiosensitization of FMdC.
DNA-damaging agents are known to result in perturbation of
cell-cycle progression. Cells with damaged DNA arrest at check-
points in the G1 or the S phase, to prevent replication of damaged
DNA, or in G2 to prevent aberrant mitosis (Hartwell and Kastan,
1994). The current analysis of cell-cycle distribution in WiDr cells
shows that FMdC alone causes predominantly S-phase arrest, and
that the addition of PTX abrogates this arrest in a dose-dependent
manner, resulting in enhancement of FMdC cytotoxicity. Similarly,
other authors have observed enhancement of the cytotoxicity of
DNA-damaging agents by 7-hydroxystaurosporine (UCN-01), a
selective protein-kinase-C inhibitor. In their experiments, UCN-01
was used to abrogate S-phase arrest in order to enhance the
cytotoxicity of camptothecin or cisplatin in human colon-cancer
cells and in Chinese-hamster ovary cells (Bunch and Eastman,
1997; Shao et al., 1997). The preferential potentiation of camptothe-
FIGURE 6 – Effect of PTX on cell-cycle distribution of WiDr cells
treated with FMdC and irradiation. Cells were treated with 30 nM
FMdC for 48 hr, then irradiated, and 0.5 mM PTX was added
immediately. Cells were harvested 24 hr after irradiation before flow
cytometry. a, p , 0.01 relative to control; b, p , 0.01 relative to 6 Gy;
c, p , 0.05 relative to 6 Gy; d, p , 0.05 relative to FMdC-treated and
irradiated (6 Gy) cells.
FIGURE 5 – Alleviation of FMdC-induced S-phase arrest by PTX. Cells were treated with 30 nM FMdC in the presence of 0.25 to 1.0 mM PTX
for 24 hr, and then harvested. (a) Cells analyzed by flow cytometry. (b) Quantitation of data in (a), *p , 0.05 compared with S-phase in cells
treated with FMdC alone.
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cin cytotoxicity by UCN-01 is observed in p53-defective tumor
cells (Shao et al., 1997). Perras et al. (1993) reported that PTX
enhances cisplatin cytotoxicity in a human ovarian cell line (BG-1),
and postulate that this toxicity enhancement is probably due to the
suppression of DNA synthesis or DNA repair as cells enter the S
phase. Our results thus represent independent observations that
enhancement of the cytotoxic effect of different DNA-damaging
agents occurs by abrogating S-phase arrest. The hypothesis that
S-phase-specific drugs act partially by blocking tumor cells in S
phase suggests that studies combining those drugs with methylxan-
thine derivatives such as PTX should be seriously considered. This
concept is in accordance with findings of our group showing a
synergistic effect between PTX and 5-fluorouracil (data not shown).
The human colon-cancer cell line WiDr has a mutated p53 gene,
and fails to arrest in G1 after ionizing radiation (Li et al., 1995). If
cells lack a post-irradiation G1 block, they are still able to arrest the
cell cycle at the G2/M transition. We have shown the ability of PTX
to modify the radiation-induced G2 delay and hence to act as a
radiosensitizer (Li et al., 1998). Loss of the p53-dependent G1
arrest makes the ability of the cells to arrest in G2 crucial for
survival after irradiation. We analyzed radiation-induced G2 arrest
in human colon-cancer (WiDr) and cervical-cancer (C33-A, C4-I)
cell lines with defective p53 (Li et al., 1998). PTX is effective at
abrogating this arrest and enhances radiation-induced cytotoxicity.
The importance of the G2 delay following FMdC and irradiation is
suggested in the present study by the correlation between PTX
abrogation of G2 arrest and radiosensitization. Alleviation of the
G2/M block by PTX might explain, at least in part, the combined
radiosensitizing effect of FMdC and PTX. As reported by Smeets et
al. (1994), radiation-induced G2 arrest is associated with down-
regulation of cyclin B/cdc2 kinase activity, and methylxanthines
such as caffeine can reverse this effect and enhance cytotoxicity
(Hain et al., 1993).
Taken together, our findings suggest, first, the existence of both
S-phase and G2-phase arrest induced by FMdC and irradiation respec-
tively. Second, the S-phase and G2-phase blocks can be abrogated by
PTX. A checkpoint-based strategy may therefore offer a way to
selectively enhance the cytotoxicity of DNA-damaging agents, provided
less toxic derivatives of PTX can be developed.
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